| Introgen Therapeutics Highlights Summary ADVEXIN Data At The Third ...
Introgen Therapeutics, Inc. (NASDAQ:INGN) reported summary data from clinical studies of its lead product, ADVEXIN®. These data confirm and extend previous biomarker data correlating the abnormal p53 biomarker with increased tumor responses following ADVEXIN treatment and support its use as a biomarker to predict ADVEXIN efficacy. Additionally, data are being presented demonstrating clinical benefit of ADVEXIN in a patient with a rare inherited form of cancer known as Li-Fraumeni Syndrome (LFS), a genetic disorder characterized by inherited mutations in the p53 tumor suppressor gene. These data have been the subject of previous presentations at scientific and medical conferences.
These data are being presented at the 3rd International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome in Lyon, France, organized by the International Agency for Research on Cancer and the European community.
A Beautiful Beginning: Look like a Knock Out by the New Year
It's almost natural to think of winter as being a dark and sometimes dull season. But adopting the right beauty measures and making them a routine can keep you looking vibrant no matter how drab it gets outside. From skincare to great hair, just a few changes can make a big difference.Face value. One of the hottest skin treatments available right now is the micro peel, and it's no wonder. "They're the most result driven because they turn over cellular buildup and make the clarity of skin a lot lighter and look a lot fresher," says Celeste Bullar, esthetician from Egyptian Revival Day Spa, in Carterville."Micro peels are good for not only dry skin, but also acne," she says. "Skin clarity is also improved through other procedures such as full or mini facials, and a variety of body wraps."Protecting skin from the sun is important in the winter, too.
Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and ...
BERKELEY, Calif., Nov. 26 /PRNewswire-FirstCall/ -- In a paper appearing online in the December issue of The European Journal of Immunology (Vol. 37, Issue 12), Dynavax scientists report the results of studies made possible under a grant from the Alliance for Lupus Research (ALR). In the article entitled, "Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms", the data show that Dynavax's proprietary IRS 954, a specific inhibitor of two Toll-like receptors, TLR7 and TLR9, can prevent progression of disease when injected in the lupus prone (NZBxNZW)F1 mice. The authors observed a significant reduction of serum levels of nucleic acid specific autoantibodies, the hallmark of systemic lupus erythematosus.
|
